2022
864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED
INZUCCHI S, BHATT D, PITT B, SZAREK M, CANNON C, LEWIS J, RIDDLE M, KOSIBOROD M, CHERNEY D, DWYER J, SCIRICA B, BAILEY C, BANKS P, DIAZ R, RAY K, UDELL J, LOPES R, LEITER L, STEG P. 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED. Diabetes 2022, 71 DOI: 10.2337/db22-864-p.Peer-Reviewed Original ResearchGlucose-lowering medicationsPre-specified subgroupsNovartis Pharmaceuticals CorporationGlaxoSmithKline plcDaiichi SankyoDual SGLT1Baseline A1CBaseline eGFRPfizer Inc.Bristol-Myers Squibb CompanyLexicon PharmaceuticalsOutcome trialsCSL BehringNovo NordiskNovartis AGAdvanced chronic kidney diseaseType 2 diabetes patientsEli LillyAmgen Inc.Lower baseline eGFROverall trial populationCKD stage 4Primary composite outcomeSpeakers bureauCardiovascular outcome trials
2021
Strategies to Minimize Iodinated Contrast Volume in Patients with Chronic Kidney Disease Undergoing Peripheral Vascular Interventions
Lee SR, Dardik A, Chaar CIO. Strategies to Minimize Iodinated Contrast Volume in Patients with Chronic Kidney Disease Undergoing Peripheral Vascular Interventions. Annals Of Vascular Surgery 2021, 73: 490-495. PMID: 33556507, DOI: 10.1016/j.avsg.2021.01.081.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsChronic kidney diseaseVascular interventionsPostcontrast acute kidney injuryChronic limb threatening ischemiaSuccessful endovascular revascularizationAcute kidney injuryCKD stage 4Limb threatening ischemiaPC-AKIEndovascular revascularizationKidney injuryUse of ICMContrast volumeKidney diseaseIntravascular lesionsContrast mediumPatientsStage 4InterventionRiskRevascularizationIschemiaInjuryTherapy
2015
Chapter 21 Neurologic Complications of Chronic Kidney Disease
Murray A, Seliger S, Stendahl J. Chapter 21 Neurologic Complications of Chronic Kidney Disease. 2015, 249-265. DOI: 10.1016/b978-0-12-411602-3.00021-4.Peer-Reviewed Original ResearchCKD patientsCognitive impairmentStage 3 CKD patientsCKD stage 4Chronic kidney diseaseErythropoiesis-stimulating agentsRisk of strokeVascular cognitive impairmentUremic polyneuropathyUremic pruritusESRD patientsNeurologic complicationsNeurologic outcomeStroke preventionAggressive treatmentDialysis initiationRenal functionStroke riskPeripheral neuropathyMedication noncomplianceAtrial fibrillationCerebrovascular diseaseAdverse outcomesKidney diseaseCKD model
2011
Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply